SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Paracelsian Inc (PRLN)
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Harvey Allen who wrote (263)7/23/1996 11:32:00 PM
From: Michael Yang   of 4342
 
Harvey,

The combination therapies are certainly far ahead of PRLN. We knew this at the beginning of the year. However, as Rick pointed out earlier, the protease inhibitors and other nucleoside analogues (like AZT) are very expensive. Combination therapies will cost insurances a lot money and, as of current, mostly available to those who can afford it. PN355 was also effectively used together with AZT. So it is possible that the PN355 will be used as cheaper alternative or to reduce the dosages of either nucleosides or protease inhibitors. Also, extracts from the plant should be readily available.

What worries me much more is this bear market. Blood baths! Cyto had a product approved yesterday, and the market drove it down today. PRLN has resisted this current down turn very well (compared to my other biotech holdings). I am very hopeful that the Cohn's paper brings some positive responses.

Good luck,

Michael
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News